JP4959919B2 - 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物 - Google Patents

官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物 Download PDF

Info

Publication number
JP4959919B2
JP4959919B2 JP2003559480A JP2003559480A JP4959919B2 JP 4959919 B2 JP4959919 B2 JP 4959919B2 JP 2003559480 A JP2003559480 A JP 2003559480A JP 2003559480 A JP2003559480 A JP 2003559480A JP 4959919 B2 JP4959919 B2 JP 4959919B2
Authority
JP
Japan
Prior art keywords
drug
propellant
polyethylene glycol
excipient
glass bottle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003559480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502086A (ja
JP2006502086A5 (https=
Inventor
エス． ステフリー，ジェイムス
シー． デュアン，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of JP2006502086A publication Critical patent/JP2006502086A/ja
Publication of JP2006502086A5 publication Critical patent/JP2006502086A5/ja
Application granted granted Critical
Publication of JP4959919B2 publication Critical patent/JP4959919B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003559480A 2001-12-21 2002-12-20 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物 Expired - Fee Related JP4959919B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34278701P 2001-12-21 2001-12-21
US60/342,787 2001-12-21
PCT/US2002/041299 WO2003059317A2 (en) 2001-12-21 2002-12-20 Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Publications (3)

Publication Number Publication Date
JP2006502086A JP2006502086A (ja) 2006-01-19
JP2006502086A5 JP2006502086A5 (https=) 2006-03-02
JP4959919B2 true JP4959919B2 (ja) 2012-06-27

Family

ID=23343270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559480A Expired - Fee Related JP4959919B2 (ja) 2001-12-21 2002-12-20 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物

Country Status (8)

Country Link
US (1) US7718162B2 (https=)
EP (1) EP1458357B1 (https=)
JP (1) JP4959919B2 (https=)
AT (1) ATE424186T1 (https=)
AU (1) AU2002367032B8 (https=)
CA (1) CA2470520A1 (https=)
DE (1) DE60231428D1 (https=)
WO (1) WO2003059317A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470520A1 (en) 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
JP2005514440A (ja) * 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー アミドおよび／またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物
JP2005514437A (ja) * 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー イオン対複合体を含む医薬用エアロゾル製剤
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0620700D0 (en) 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
DK2480197T3 (en) 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
US11981619B2 (en) 2017-07-07 2024-05-14 Basf Se Alkoxylated esteramines and salts thereof
JP7657496B2 (ja) * 2021-12-02 2025-04-07 レジェロン，インコーポレイテッド 多機能用途を有する天然賦形剤およびその調製プロセス

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1163028B (de) * 1960-03-09 1964-02-13 Hoechst Ag Verfahren zur Polymerisation von Vinylchlorid
JPS63503304A (ja) 1986-03-10 1988-12-02 ブルグハルト，クルト 医薬製剤およびその製造方法
AU601176B2 (en) 1986-03-10 1990-09-06 Kurt Burghart Benzodiazepine aerosols
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO1992000061A1 (en) 1990-06-29 1992-01-09 Fisons Plc Pressurised aerosol compositions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
ATE177941T1 (de) 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
ES2107203T3 (es) 1993-03-17 1997-11-16 Minnesota Mining & Mfg Una formulacion de aerosol que contiene un adyuvante de dispersion derivado de un diol-diacido.
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
JPH09506097A (ja) 1993-12-02 1997-06-17 アボツト・ラボラトリーズ 非ｃｆｃ噴射剤と共に用いるエアロゾル薬物調剤
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6218353B1 (en) 1997-08-27 2001-04-17 Micell Technologies, Inc. Solid particulate propellant systems and aerosol containers employing the same
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
BR9914799A (pt) 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
US6258857B1 (en) 1999-02-04 2001-07-10 Kyowa Industrial Co., Ltd. Internal liquid composition contained as internal liquid in a releasing container and releasing container product
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US7217409B2 (en) 2000-09-22 2007-05-15 Smithkline Beecham Corporation Alkanoic acid derivatives
CZ20033182A3 (cs) 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
JP2005514440A (ja) 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー アミドおよび／またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物
CA2470520A1 (en) 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Also Published As

Publication number Publication date
DE60231428D1 (de) 2009-04-16
JP2006502086A (ja) 2006-01-19
EP1458357A2 (en) 2004-09-22
AU2002367032B2 (en) 2008-09-25
AU2002367032B8 (en) 2008-10-23
WO2003059317A2 (en) 2003-07-24
ATE424186T1 (de) 2009-03-15
AU2002367032A1 (en) 2003-07-30
US7718162B2 (en) 2010-05-18
EP1458357B1 (en) 2009-03-04
CA2470520A1 (en) 2003-07-24
WO2003059317A3 (en) 2003-11-20
US20030152521A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
EP1123120B1 (en) Medicinal aerosol formulation
AU2001245190B2 (en) A medicinal aerosol formulation
JP4959919B2 (ja) 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物
ITMI20000312A1 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva
BG107256A (bg) Стабилен фармацевтичен разтвор за инхалатори с отмервана доза под налягане
AU2021314977B2 (en) Combination therapy for inhalation administration
US7186402B2 (en) Medicinal aerosol compositions with an amide and/or ester containing excipient compound
US20030147814A1 (en) Medicinal aerosol formulations comprising ion pair complexes
HK1097777B (en) Medicinal aerosol formulation
HK1041835B (en) Medicinal aerosol formulation
HK1176290A1 (en) Inhalation solution
HK1176290B (en) Inhalation solutions
HK1079425A1 (zh) 福莫特罗超细制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120322

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150330

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees